Progress of CLDN18.2 in malignant tumors of digestive tract
10.3760/cma.j.cn115355-20230912-00102
- VernacularTitle:CLDN18.2在消化道恶性肿瘤中的研究进展
- Author:
Zhangcai WU
1
;
Yan ZHANG
;
Xi CHEN
Author Information
1. 福建医科大学福总临床医学院，福州 350025
- Keywords:
Digestive system neoplasms;
CLDN18.2;
Molecular targeted therapy;
Immunotherapy
- From:
Cancer Research and Clinic
2024;36(11):872-876
- CountryChina
- Language:Chinese
-
Abstract:
Claudins (CLDN) 18.2, a member of transmembrane protein family, belongs to a subtype of the tight junction protein family. It is highly expressed in a variety of tumor tissues of digestive system, but rarely expressed in normal tissues. Therefore, it is a potential new target for targeted therapy and immunotherapy. Abnormal expression of CLDN18.2 can damage epithelial cells and endothelial cells, which plays an important role in the invasion and metastasis of a variety of malignant tumors of epithelial origin. The expression level of CLDN18.2 is significantly increased in gastric cancer, esophageal cancer and other malignant tumors of digestive tract, which indicates the possible key role of CLDN18.2 in the progression of tumors. Therefore, CLDN18.2 can be used as potential therapeutic targets. This article reviews the role of CLDN18.2 in basic research and clinical applications of digestive tumors.
